Safety Concerns with Phenylephrine in Children Under 6 Years

Primary Safety Concerns

The American Academy of Allergy, Asthma, and Immunology recommends that phenylephrine and other oral decongestants should be avoided in children under 6 years of age due to serious safety concerns, including documented fatalities, severe neurological toxicity, and cardiovascular complications 1, 2, 3, 4
Between 1969 and September 2006, there were 4 documented fatalities specifically associated with phenylephrine in children under 6 years, as part of 54 total decongestant-related deaths 1, 3
Of these decongestant fatalities, 43 occurred in infants below 1 year of age, highlighting the extreme vulnerability of the youngest children 1, 3
Drug overdose and toxicity were common mechanisms, often resulting from use of multiple cold/cough products simultaneously, medication errors, accidental exposures, and dosing confusion 1, 3
Use in infants and young children has been directly associated with agitated psychosis, ataxia, hallucinations, and death, even at recommended doses 2, 4, 5
These agents may cause increased stimulatory effects resulting in tachyarrhythmias, insomnia, and hyperactivity, particularly when combined with other stimulant medications 2, 4
The narrow margin between therapeutic and toxic doses in children under 1 year significantly increases the risk for cardiovascular and CNS side effects 3

The efficacy of phenylephrine as an oral decongestant has not been well established, as it is extensively metabolized in the gut, making it less effective than pseudoephedrine 2, 4
Controlled trials have shown that antihistamine-decongestant combination products are not effective for symptoms of upper respiratory tract infections in young children 1, 2, 3

The FDA's Nonprescription Drugs and Pediatric Advisory Committees recommended that OTC medications used to treat cough and cold no longer be used for children below 6 years of age 1, 2, 3
The American Academy of Allergy, Asthma, and Immunology explicitly states that the use of these OTC drugs generally should be avoided in all children below 6 years of age due to potential toxicity 1, 3

Gentle nasal suctioning with bulb syringe or nasal aspirator to clear secretions and improve breathing is a recommended first-line non-pharmacologic option 7
Isotonic or hypertonic saline irrigation provides modest symptom relief with minimal side effects and good patient acceptance 7, 8
Maintain adequate hydration through continued breastfeeding or formula feeding to help thin secretions 7
Use a supported sitting position during feeding and rest to help expand lungs and improve respiratory symptoms 7
Intranasal corticosteroids are the most effective medication class for controlling nasal congestion in allergic rhinitis, with excellent safety profiles in children 1, 8
Second-generation antihistamines have been shown to be well tolerated with very good safety profiles in young children when used for allergic conditions 1, 2, 3, 8